GMAB 6-K: SEC filing

Genmab

Filed with the SEC on Nov 5, 2026 · accession 0001434265-26-000146

GMAB filed a 6-K (foreign company report) with the SEC on Nov 5, 2026. Genmab reported Q3 2026 financial results with revenue up 22% to $3,238 million for the first nine months, driven by higher DARZALEX and Kesimpta royalties and EPKINLY sales. The stock moved -4.3% by the first close after the filing.

Summary of the filing

Genmab reported Q3 2026 financial results with revenue up 22% to $3,238 million for the first nine months, driven by higher DARZALEX and Kesimpta royalties and EPKINLY sales. The company also announced positive Phase 3 topline results for epcoritamab, Rina-S, and petosemtamab, supporting multiple regulatory submissions and potential launches in 2027.

For details, click here →How to read a 6-K →

Key details

Revenue for first nine months of 2026$3.2B

Royalty revenue for first nine months of 2026$2.7B

DARZALEX net sales by J&J for first nine months of 2026$12.4B

EPKINLY/TEPKINLY global net sales for first nine months of 2026$491.0M

Operating profit for first nine months of 2026$986.0M

Adjusted operating profit for first nine months of 2026$1.1B

IssuerGenmab A/S

Partner for epcoritamabAbbVie Inc.

Darzalex royalty sourceJ&J

Acquired companyMerus

Chief executive officerJan van de Winkel

How GMAB stock reacted

Close before

$55.12

Nov 4, 2026

First close after

-4.32%

$52.74

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for GMAB, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for GMAB?

Click here

Frequently asked questions

What did GMAB file with the SEC on Nov 5, 2026?

GMAB filed a 6-K (SEC filing). Genmab reported Q3 2026 financial results with revenue up 22% to $3,238 million for the first nine months, driven by higher DARZALEX and Kesimpta royalties and EPKINLY sales. The company also announced positive Phase 3 topline results for epcoritamab, Rina-S, and petosemtamab, supporting multiple regulatory submissions and potential launches in 2027.

How do I read a 6-K?

How foreign companies listed in the US report news and events — like an 8-K for them. Look at the exhibit names: "results", "resign", "notice" tell you the topic. Many 6-Ks are routine (meeting notices); results and leadership changes matter most.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 6-K (foreign company report): How foreign companies listed in the US report news and events — like an 8-K for them.

How did GMAB stock react to this filing?

GMAB closed at $55.12 before the filing and $52.74 on Nov 5, 2026 (-4.32%).

Other GMAB SEC filings

Get alerts when GMAB files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

GMAB overview GMAB analysis GMAB news Latest SEC filings